Navigation Links
Goserelin improves long-term survival in premenopausal women with early breast cancer
Date:2/24/2009

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, according to trial data reported in the February 24 online issue of the Journal of the National Cancer Institute.

Systematic reviews have shown that lutenizing hormone-releasing hormone agonists, including goserelin, reduce the risk of disease recurrence and death due to breast cancer in premenopausal women. However the long-term impact of goserelin was not known, particularly in comparison to women who did or did not take tamoxifen.

Women with breast cancer were randomly assigned to take goserelin (Zoladex), tamoxifen, both agents, or neither drug for two years in the Zoladex in Premenopausal Patients study. In this analysis, which included 2,706 women, Allan Hackshaw, of the Cancer Research UK Trials Centre at University College London, and colleagues examined the long-term impact of the agents on various outcomes, including the risk of the cancer returning and the risk of dying from breast cancer or any cause.

The effect of two years of goserelin treatment was comparable to that conferred by two years of tamoxifen. Among patients who took goserelin alone, there were 13.9 fewer events per 100 women 15 years after starting treatment, compared with those who did not take either drug. Among women who took both drugs, the benefit of adding goserelin to tamoxifen was smaller (2.8 fewer events per 100 patients) and did not reach statistical significance.

The number of breast cancer deaths was lower by 8.5 per 100 women in those who took goserelin alone, compared to those who took neither drug. The difference was statistically significant. Among those who added goserelin to tamoxifen, there was an additional reduction of 2.6 deaths per 100 women. But again, the additional reduction was not statistically significant.

"In summary, long-term follow-up of our large trial showed that goserelin had a demonstrable effect on survival and recurrence 15 years after starting treatment and is as effective as tamoxifen when each are given for 2 years," the authors write. "It may be that women who are unlikely to complete 5 years of tamoxifen tablets may prefer 2 years of goserelin injections."


'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Physical fitness improves spatial memory, increases size of brain structure
2. Knowledge of genetics improves uncertain medication
3. Weight loss improves fatty liver disease, researchers find
4. Navigation System Significantly Improves the Surgical Accuracy of Total Knee Replacement for Arthritis Patients
5. Durability of dental fillings improves if the enzyme activity of teeth is inhibited
6. Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma
7. Quick Stroke Treatment Improves Outcomes
8. Michigan Collaboration Saves Lives, Improves Outcomes for Heart Surgery Patients
9. Exercise improves leg pain caused by arterial disease
10. New Reaxys Solution Improves Workflow Quality and Efficiency for Chemists
11. When less attention improves behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could ... after surgery, though activity levels decline over time. The study, presented today at ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and application ... arm of one of world’s largest healthcare services providers. , According to ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... In vitro diagnostics market firm Kalorama Information ... least ten diagnostic companies have successfully completed financings.  The ... a loan facility.  The size of these financings ranged ... Information provides a monthly IVD Market Trends Report ... "Diagnostics deals ...
Breaking Medicine Technology: